iSTAR Medical announces EUR 40m Series C Financing

To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM

WAVRE, Belgium — 5 September 2019:  iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced the completion of a €40m Series C financing. The financing was led by healthcare specialist funds LSP and Gimv, with participation by Earlybird and BNP Paribas Fortis Private Equity. Existing shareholders including Capricorn Partners, Walloon Region Investment Fund (SRIW) and Belgian Federal Investment Fund (SFPI‐FPIM) also participated. This financing will support the development of iSTAR Medical’s MINIjectTM device along the path to commercialisation in Europe and the United States.

Read more

iSTAR Medical’s MINIject shows consistent results at 18-month follow-up in first-in-human trial (STAR-I)

WAVRE, Belgium — 10 July 2019: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIjectTM device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year.

Read more

iSTAR Medical’s MINIject maintains exceptional results in first-in-human trial one year post-surgery (STAR-I)

WAVRE, Belgium — 19 December 2018: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced exceptional one-year results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial, for the MINIjectTM device in a standalone setting. Results continue to show that MINIject is safe and highly effective in achieving significant intraocular pressure (IOP) reduction, as well as easing medication burden in glaucoma patients.

Read more

iSTAR Medical’s MINIject delivers exceptional 6-month results in first-in-human trial

WAVRE, Belgium — 16 May 2018: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced exceptional six-month results of their first-in-human (FIH) micro-invasive glaucoma surgery (MIGS) trial for the MINIjectTM device in a standalone setting. Results show MINIject to be safe and highly effective in achieving significant intraocular pressure (IOP) reduction in glaucoma patients.

Read more

iSTAR Medical completes enrolment of first-in-human MIGS trial

Novel MINIject device made from STAR® material successfully implanted in 25 patients

WAVRE, Belgium — 17 October 2017: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the completion of enrolment in their first-in-human (FIH) micro-invasive glaucoma surgery (MIGS) trial for the MINIjectTM device.

Read more

iSTAR Medical Strengthens Board with Two Senior Appointments

Martin Wax, M.D. and Marc Nolet de Brauwere appointed to Board of Directors

WAVRE, Belgium — 28 June 2016: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the appointment of Martin Wax, M.D. and Marc Nolet de Brauwere to the Board of Directors. Dr Martin Wax is a scientific expert in glaucoma with over 30 years of experience in industry and academia. He is currently the Chief Medical Officer and Executive Vice‐President of R&D at PanOptica, Inc., and was formerly Vice‐President and Head of Discovery Research and Pre‐Clinical Sciences at Alcon Laboratories.

Read more

iSTAR Medical Secures €10 Million Financing

WAVRE, Belgium — 12 April 2016: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the closing of a €10 million Series B equity financing. Existing shareholders including Capricorn Venture Partners and Walloon Region Investment Fund (SRIW) contributed to the round, which was joined by new investors Belgian Federal Investment Fund (SFPI‐FPIM), Fond Européen des Matériaux, Start‐Up and several private investors.

Read more

iSTAR Medical Appoints Medical Device Executive Michel Lussier as Chairman of its Board of Directors

ISNES, Belgium, April 27, 2015 /PRNewswire/ — iSTAR Medical SA, a Belgium ophthalmic device company, announced today the appointment of Michel Lussier as Chairman of the company’s Board of Directors.

Read more

iStar Medical Announces First Patient Implanted with STARflo™ Glaucoma Drainage Device in European Clinical Trial

Isnes, Belgium (Oct 30, 2014) – iSTAR Medical SA, a privately held ophthalmic device company, announced today that the first patient in its European multi-center clinical trial has been successfully implanted with the STARflo glaucoma drainage device.

Read more

iSTAR Medical appoints Michel Vanbrabant Chief Executive Officer

Isnes, Belgium (July 16, 2014) – iSTAR Medical SA, a privately held ophthalmic device company, announced today that Michel Vanbrabant has been appointed Chief Executive Officer and member of the Board of Directors.

Read more